- Karyopharm Pharmaceuticals (KPTI) closed Monday down ~21% after disclosing a “2026 Leadership Cash Retention Program” for some of its top executives.
- Those who will benefit from it are its CEO, CFO, chief development officer, and chief medical officer.
- CEO Richard
